{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibdpsfr56spb35ifp3przgwde2rchfhwb3onjkquxaoi56j7u4tce",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mjfrb6qylld2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/04/13/revolution-pancreatic-cancer-pill-fda-rejects-replimune-cancer-drug/?utm_campaign=rss",
  "publishedAt": "2026-04-13T13:02:52.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who got chemotherapy",
  "title": "STAT+: Pharmalittle: We’re reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more",
  "updatedAt": "2026-04-13T13:02:57.000Z"
}